GlassScriptPhysician profile
D'Anna Cain
NPI 1538653829
$5,849.62
in general payments reported to CMS, 2019-2025
28 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,336 · 2022: $2,983 · 2023: $632 · 2024: $515 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,393.39 | 2022-2025 | Minimed 780g |
| Abbvie INC. | $586.23 | 2021-2024 | |
| Novo Nordisk INC | $584.98 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $427.36 | 2021-2024 | Zepbound, Mounjaro |
| Pfizer INC. | $337.61 | 2021-2025 | |
| Glaxosmithkline, LLC. | $262.50 | 2021-2024 | Shingrix, Bexsero, Arexvy |
| Astrazeneca Pharmaceuticals LP | $241.45 | 2021-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $148.69 | 2022-2024 | Rexulti |
| Amarin Pharma, INC. | $145.95 | 2021 | |
| Astellas Pharma US INC | $141.78 | 2023-2024 | Veozah |
| Corcept Therapeutics | $85.30 | 2021-2022 | |
| Esperion Therapeutics, INC. | $63.83 | 2021 | |
| Eisai INC. | $42.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $42.25 | 2021-2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $39.00 | 2024-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $38.17 | 2021-2022 | |
| Sanofi Pasteur INC. | $29.28 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $28.29 | 2021-2022 | |
| Abbott Laboratories | $28.13 | 2023 | Freestyle Libre 3 |
| Nevro Corp. | $23.71 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $23.70 | 2024 | Zilretta, Iovera, Exparel |
| Tris Pharma INC | $23.17 | 2025 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.97 | 2024 | Ofev |
| Endo Pharmaceuticals INC. | $21.06 | 2021 | |
| Radius Health, INC. | $19.67 | 2024 | Tymlos |
| Boston Scientific Corporation | $16.95 | 2025 | General - Pain Management |
| Dexcom, INC. | $16.64 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw D'Anna Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.